Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an ARCH scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

The CIHR grant entitled "A Multifaceted Function for Dipeptidase-1 in Kidney Injury" was awarded to a research team at the University of Calgary led Dr. Daniel Muruve. Dr. Muruve is also the Chief Science Officer of Arch. The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD.

Quote from Dr. Daniel Muruve:

"The cause of kidney disease is generally unknown and as a result, there are currently few treatments for acute kidney injury (AKI) or CKD. The only treatment for kidney failure, at present, is life support using dialysis or kidney transplantation. A better approach is to find new treatments for AKI and CKD that prevent kidney failure altogether. We have strong evidence that inflammation and DPEP-1 play very important roles in kidney injury and disease. We plan to study exactly how DPEP-1 contributes to kidney disease, including CKD and how to best target its function therapeutically."

About DPEP-1 and Organ Inflammation

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In the publication, the enzyme DPEP-1 was identified, for the first time, as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. Their findings established DPEP-1 as a novel therapeutic target for diseases of these organs where inflammation plays a major role and demonstrated that DPEP-1 is the target of the Company's lead drug candidate, LSALT Peptide. The publication can be found at the following link:

"Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver"

Subsequently in 2022, Dr. Muruve and his team explained in a publication in Science Advances how DPEP-1 regulates inflammation in the kidney. The publication can be found at the following link:

"Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury"

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 62,398,825 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements, except as required by law.

The science and medical contents of this release have been approved by the Company's Chief Science Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release


For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARCH
The Conversation (0)
First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced that it is reviewing its extensive drilling inventory for follow up operations to its planned Leduc anomaly drill ("7-15") targeting light oil. This program may include drilling its proven undeveloped 1, 3 location ("7-30"), a follow up well on the Leduc anomaly, or another one of 12 primary Leduc prospects identified on its proprietary 3D seismic at Worsley. Other operations include completion and testing of the existing 5-27 horizontal well, along with the re-entry and completion of an existing vertical well bore at east Worsley, both targeting helium-enriched natural gas in the Blue Ridge formation to establish a regional, repeatable play.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
First Helium Closes Upsized $3.64 Million Placement

First Helium Closes Upsized $3.64 Million Placement

Not for distribution to United States newswire services or for dissemination in the United States.

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced the closing of its upsized non-brokered private placement financing which was previously announced in the Company's press release dated October 16, 2024 and October 21, 2024. First Helium issued 60,666,671 units ("Units") at a price of $0.06 per Unit for gross proceeds of $3,640,000.26 (the "Offering) . All monetary figures in Canadian Dollars.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GTI Energy

Lo Herma ISR Uranium Project, Resource Drilling Funded

Following the recently completed placement to sophisticated and institutional shareholders, GTI Energy Ltd (GTI or Company) is pleased to provide an update on the upcoming resource expansion drilling program at the Lo Herma ISR uranium project in Wyoming’s Powder River Basin (PRB). In advance of further news related to progress of the planned drill program at Lo Herma, the following provides a summary of the resource expansion potential and objectives of the 2024 Phase II drilling.

Keep reading...Show less
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Phase 12 pivotal study met the primary safety and efficacy endpoints –

51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff –

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
RUA GOLD Provides an Update on the Reefton Drilling Program and the next phase of drill targets

RUA GOLD Provides an Update on the Reefton Drilling Program and the next phase of drill targets

RUA GOLD Corporation (CSE: RUA) (OTC: NZAUF) (WKN: A4010V) ("RUA GOLD" or the "Company") is pleased to provide an exploration update for the Reefton Project on the South Island of New Zealand .

  • Preliminary results confirm the Pactolus system extends south for 550 meters along strike and is well mineralized on surface.
  • The Company is analyzing the results to better understand the plunge and tenor of the ore shoots at this early stage of exploration.
  • The Company has developed multiple new high-grade targets at past producing mines in the Murray Creek area for drill testing in Q2/2024.

Pactolus

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Rox Resources

High grade Assay Results Continue at Youanmi

West Australian gold exploration and development company, Rox Resources Limited (“Rox” or “the Company”) (ASX: RXL), has received the final batch of assays from its 11,000m DD and RC program at the Youanmi Gold Project in WA.

Keep reading...Show less
Alice Queen

Drilling Commenced at Viani in Fiji

Alice Queen Limited (ASX:AQX) (“Alice Queen” or the “Company”) is pleased to announce that drilling has commenced at its 100% owned Viani Project in Vanua Levu, Fiji (see Image 1). The initial planned three-hole diamond drilling program will test for high-grade epithermal gold-style mineralisation intersected at the Viani Project by historic drilling.

Keep reading...Show less
Firefly Metals logo

FireFly Drills its Best Hole Yet with Assay of 86.3m at 3.7% CuEq

Latest drilling returns very thick intersections with exceptional grades, outlining a rich area of mineralistion which will form part of the next Resource update

FireFly Metals Ltd (ASX: FFM) (“Company” or “Firefly”) is pleased to announce its best assays yet at the Green Bay copper-gold project.

Keep reading...Show less
Corazon Mining

Strategic Expansion of MacBride Base & Precious Metal Project in Canada

Acquired ground more than doubles Corazon’s prospective landholding / Aerial geophyical survey extended to test new tenure / Work underway defining priority targets for early 2025 drill program

Corazon Mining Limited (ASX: CZN) (Corazon or Company) is pleased to announce the strategic expansion of its MacBride Base and Precious Metals Project (MacBride or Project) in the Lynn Lake district, of Manitoba, Canada.

Keep reading...Show less

Latest Press Releases

Related News

×